Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$46.72 -1.4%	$47.47	$41.90 ▼ $63.33	$96.38B	0.36	12.75 million shs	9.93 million shs
MRK Merck & Co., Inc.	$79.35 -0.8%	$79.37	$73.31 ▼ $128.73	$200.78B	0.39	13.50 million shs	11.58 million shs
PFE Pfizer	$24.27 -0.8%	$24.07	$20.92 ▼ $31.54	$139.12B	0.58	41.93 million shs	33.44 million shs
ZTS Zoetis	$147.31 -0.9%	$160.77	$139.70 ▼ $200.33	$66.16B	0.91	2.62 million shs	3.00 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	0.00%	+1.04%	+1.14%	-3.17%	+11.16%
MRK Merck & Co., Inc.	0.00%	-4.06%	+0.92%	+2.64%	-36.42%
PFE Pfizer	0.00%	-4.64%	+2.05%	+10.83%	-18.39%
ZTS Zoetis	0.00%	-4.07%	-5.50%	+1.20%	-16.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.8502 of 5 stars	3.2	3.0	4.2	4.0	2.6	3.3	1.3
MRK Merck & Co., Inc.	4.9946 of 5 stars	3.2	4.0	5.0	4.2	3.5	2.5	3.8
PFE Pfizer	4.9724 of 5 stars	3.2	3.0	4.2	4.5	3.3	1.7	3.1
ZTS Zoetis	4.9785 of 5 stars	4.4	5.0	4.2	0.4	2.9	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$57.69	23.49% Upside
MRK Merck & Co., Inc.	2.43	Hold	$108.69	36.98% Upside
PFE Pfizer	2.45	Hold	$28.55	17.66% Upside
ZTS Zoetis	2.70	Moderate Buy	$204.63	38.90% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRK, BMY, and ZTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
7/10/2025	MRK Merck & Co., Inc.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$99.00 ➝ $98.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.97	$5.81 per share	8.04	$8.08 per share	5.78
MRK Merck & Co., Inc.	$64.17B	3.10	$9.39 per share	8.45	$18.33 per share	4.33
PFE Pfizer	$63.63B	2.17	$4.33 per share	5.61	$15.62 per share	1.55
ZTS Zoetis	$9.26B	7.09	$7.01 per share	21.02	$10.57 per share	13.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.50	7.67	2.48	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.55	8.01	0.83	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	7.62	8.01	0.89	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	24.68	21.82	2.46	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest PFE, MRK, BMY, and ZTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
8/5/2025	Q2 2025	ZTS Zoetis	$1.61	N/A	N/A	N/A	$2.41 billion	N/A
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.31%	N/A	92.88%	17 Years
MRK Merck & Co., Inc.	$3.24	4.08%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	7.09%	N/A	124.64%	16 Years
ZTS Zoetis	$2.00	1.36%	N/A	35.91%	14 Years

Latest PFE, MRK, BMY, and ZTS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
MRK Merck & Co., Inc.	0.69	1.41	1.16
PFE Pfizer	0.64	1.26	0.96
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.07%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

PFE, MRK, BMY, and ZTS Headlines

Recent News About These Companies

Regency Capital Management Inc. DE Makes New Investment in Zoetis Inc. (NYSE:ZTS)

July 21 at 10:17 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Holdings Decreased by Crestwood Advisors Group LLC

July 21 at 9:39 AM | marketbeat.com

Peterson Wealth Services Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 21 at 8:35 AM | marketbeat.com

Here’s Wedgewood Partners’ Investment Thesis for Zoetis (ZTS)

July 21 at 8:30 AM | insidermonkey.com

William Allan Corp Has $2.95 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 21 at 8:14 AM | marketbeat.com

Los Angeles Capital Management LLC Cuts Stock Position in Zoetis Inc. (NYSE:ZTS)

July 21 at 7:51 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by South Dakota Investment Council

July 21 at 6:18 AM | marketbeat.com

Formidable Asset Management LLC Makes New $316,000 Investment in Zoetis Inc. (NYSE:ZTS)

July 21 at 5:53 AM | marketbeat.com

Leerink Partnrs Issues Positive Estimate for Zoetis Earnings

July 21 at 2:14 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Heritage Investors Management Corp

July 20 at 8:20 AM | marketbeat.com

AustralianSuper Pty Ltd Has $14.24 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 20 at 6:39 AM | marketbeat.com

Leerink Partnrs Weighs in on Zoetis' Q3 Earnings (NYSE:ZTS)

July 20 at 2:04 AM | americanbankingnews.com

Kestra Private Wealth Services LLC Trims Holdings in Zoetis Inc. (NYSE:ZTS)

July 19 at 10:31 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Carnegie Lake Advisors LLC

July 19 at 9:11 AM | marketbeat.com

Leerink Partners Downgrades Zoetis (NYSE:ZTS) to Market Perform

July 19 at 2:47 AM | americanbankingnews.com

Is Zoetis (ZTS) a Unique Dividend Play in the Pharma Space for 2025?

July 18 at 10:28 PM | insidermonkey.com

Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View

July 18 at 3:21 PM | insidermonkey.com

Why Zoetis (ZTS) Could Beat Earnings Estimates Again

July 18 at 1:11 PM | zacks.com

Zoetis (NYSE:ZTS) Lowered to Hold Rating by Leerink Partnrs

July 18 at 12:03 PM | marketbeat.com

Diversify Advisory Services LLC Has $2.53 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 18 at 11:10 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Pictet Asset Management Holding SA

July 18 at 10:40 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

PFE, MRK, BMY, and ZTS Company Descriptions

Bristol Myers Squibb NYSE:BMY

$46.72 -0.64 (-1.36%)

Closing price 03:58 PM Eastern

Extended Trading

$46.80 +0.08 (+0.18%)

As of 07:55 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$79.35 -0.61 (-0.77%)

Closing price 03:58 PM Eastern

Extended Trading

$79.38 +0.03 (+0.04%)

As of 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.26 -0.21 (-0.84%)

Closing price 03:58 PM Eastern

Extended Trading

$24.36 +0.09 (+0.37%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$147.31 -1.29 (-0.87%)

Closing price 03:58 PM Eastern

Extended Trading

$148.35 +1.04 (+0.70%)

As of 07:56 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time